JACC:多支冠脉搭桥术中期死亡率较单支冠脉搭桥术更低

2019-09-10 MedSci MedSci原创

本研究的目的旨在评估和比较多支冠状动脉搭桥术(MAGs)与单支冠状动脉搭桥术(SAGs)在多分支冠脉病变患者中的中期疗效。 本研究纳入分析了纽约心脏注册数据库中的63402名多分支冠脉病变患者,并比较MAGs和SAGs患者的预后差异。主要终点事件是死亡率,次要终点事件包括重复的血运重建和死亡、急性心梗与卒中的复合终点事件。有20%患者接受的是MAGs治疗,术后1年,两组患者的死亡风险无明显差

本研究的目的旨在评估和比较多支冠状动脉搭桥术(MAGs)与单支冠状动脉搭桥术(SAGs)在多分支冠脉病变患者中的中期疗效。


本研究纳入分析了纽约心脏注册数据库中的63402名多分支冠脉病变患者,并比较MAGsSAGs患者的预后差异。主要终点事件是死亡率,次要终点事件包括重复的血运重建和死亡、急性心梗与卒中的复合终点事件。有20%患者接受的是MAGs治疗,术后1年,两组患者的死亡风险无明显差异(2.4% vs. 2.2% [AHR]: 1.11 95% [CI]: 0.93-1.32),术后7年,MAG组患者的死亡风险更低(12.7% vs. 14.3% AHR 0.86 95% CI 0.79-0.93),复合终点事件发生率更低(20.2% vs. 22.8% AHR 0.88 95% CI 0.83-0.93),重复的血运重建率也更低(11.7% vs. 14.6% AHR 0.80 95% CI 0.74-0.87)。


研究结果显示,多支冠状动脉搭桥术和单支冠状动脉搭桥术患者术后1年的死亡风险相似,但在术后7年,MAG组患者的死亡率更低。


原始出处:

Zaza S et al.Multiple Versus Single Arterial Coronary Bypass Graft Surgery for Multivessel Disease.JACC.2019 Sep.


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1663951, encodeId=a9901663951eb, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Wed Dec 25 03:44:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682083, encodeId=b36e168208390, content=<a href='/topic/show?id=202b309688b' target=_blank style='color:#2F92EE;'>#冠脉搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30968, encryptionId=202b309688b, topicName=冠脉搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41e27933971, createdName=ZGMFX33A, createdTime=Fri Jun 26 16:44:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854505, encodeId=df2b185450556, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Dec 03 17:44:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326330, encodeId=6db6132633023, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Sep 12 04:44:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492378, encodeId=519c14923e8cf, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Thu Sep 12 04:44:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552924, encodeId=292e155292492, content=<a href='/topic/show?id=696730966a0' target=_blank style='color:#2F92EE;'>#冠脉搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30966, encryptionId=696730966a0, topicName=冠脉搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=710114309336, createdName=yese, createdTime=Thu Sep 12 04:44:00 CST 2019, time=2019-09-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1663951, encodeId=a9901663951eb, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Wed Dec 25 03:44:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682083, encodeId=b36e168208390, content=<a href='/topic/show?id=202b309688b' target=_blank style='color:#2F92EE;'>#冠脉搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30968, encryptionId=202b309688b, topicName=冠脉搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41e27933971, createdName=ZGMFX33A, createdTime=Fri Jun 26 16:44:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854505, encodeId=df2b185450556, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Dec 03 17:44:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326330, encodeId=6db6132633023, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Sep 12 04:44:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492378, encodeId=519c14923e8cf, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Thu Sep 12 04:44:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552924, encodeId=292e155292492, content=<a href='/topic/show?id=696730966a0' target=_blank style='color:#2F92EE;'>#冠脉搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30966, encryptionId=696730966a0, topicName=冠脉搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=710114309336, createdName=yese, createdTime=Thu Sep 12 04:44:00 CST 2019, time=2019-09-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1663951, encodeId=a9901663951eb, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Wed Dec 25 03:44:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682083, encodeId=b36e168208390, content=<a href='/topic/show?id=202b309688b' target=_blank style='color:#2F92EE;'>#冠脉搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30968, encryptionId=202b309688b, topicName=冠脉搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41e27933971, createdName=ZGMFX33A, createdTime=Fri Jun 26 16:44:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854505, encodeId=df2b185450556, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Dec 03 17:44:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326330, encodeId=6db6132633023, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Sep 12 04:44:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492378, encodeId=519c14923e8cf, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Thu Sep 12 04:44:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552924, encodeId=292e155292492, content=<a href='/topic/show?id=696730966a0' target=_blank style='color:#2F92EE;'>#冠脉搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30966, encryptionId=696730966a0, topicName=冠脉搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=710114309336, createdName=yese, createdTime=Thu Sep 12 04:44:00 CST 2019, time=2019-09-12, status=1, ipAttribution=)]
    2019-12-03 hbwxf
  4. [GetPortalCommentsPageByObjectIdResponse(id=1663951, encodeId=a9901663951eb, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Wed Dec 25 03:44:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682083, encodeId=b36e168208390, content=<a href='/topic/show?id=202b309688b' target=_blank style='color:#2F92EE;'>#冠脉搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30968, encryptionId=202b309688b, topicName=冠脉搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41e27933971, createdName=ZGMFX33A, createdTime=Fri Jun 26 16:44:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854505, encodeId=df2b185450556, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Dec 03 17:44:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326330, encodeId=6db6132633023, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Sep 12 04:44:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492378, encodeId=519c14923e8cf, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Thu Sep 12 04:44:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552924, encodeId=292e155292492, content=<a href='/topic/show?id=696730966a0' target=_blank style='color:#2F92EE;'>#冠脉搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30966, encryptionId=696730966a0, topicName=冠脉搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=710114309336, createdName=yese, createdTime=Thu Sep 12 04:44:00 CST 2019, time=2019-09-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1663951, encodeId=a9901663951eb, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Wed Dec 25 03:44:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682083, encodeId=b36e168208390, content=<a href='/topic/show?id=202b309688b' target=_blank style='color:#2F92EE;'>#冠脉搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30968, encryptionId=202b309688b, topicName=冠脉搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41e27933971, createdName=ZGMFX33A, createdTime=Fri Jun 26 16:44:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854505, encodeId=df2b185450556, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Dec 03 17:44:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326330, encodeId=6db6132633023, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Sep 12 04:44:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492378, encodeId=519c14923e8cf, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Thu Sep 12 04:44:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552924, encodeId=292e155292492, content=<a href='/topic/show?id=696730966a0' target=_blank style='color:#2F92EE;'>#冠脉搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30966, encryptionId=696730966a0, topicName=冠脉搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=710114309336, createdName=yese, createdTime=Thu Sep 12 04:44:00 CST 2019, time=2019-09-12, status=1, ipAttribution=)]
    2019-09-12 zzc2214
  6. [GetPortalCommentsPageByObjectIdResponse(id=1663951, encodeId=a9901663951eb, content=<a href='/topic/show?id=03a35691e2e' target=_blank style='color:#2F92EE;'>#搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56917, encryptionId=03a35691e2e, topicName=搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=557f25711234, createdName=12498b3em16(暂无昵称), createdTime=Wed Dec 25 03:44:00 CST 2019, time=2019-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682083, encodeId=b36e168208390, content=<a href='/topic/show?id=202b309688b' target=_blank style='color:#2F92EE;'>#冠脉搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30968, encryptionId=202b309688b, topicName=冠脉搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d41e27933971, createdName=ZGMFX33A, createdTime=Fri Jun 26 16:44:00 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854505, encodeId=df2b185450556, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Dec 03 17:44:00 CST 2019, time=2019-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326330, encodeId=6db6132633023, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Sep 12 04:44:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492378, encodeId=519c14923e8cf, content=<a href='/topic/show?id=a251569194f' target=_blank style='color:#2F92EE;'>#搭桥术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56919, encryptionId=a251569194f, topicName=搭桥术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32a28924986, createdName=zzc2214, createdTime=Thu Sep 12 04:44:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552924, encodeId=292e155292492, content=<a href='/topic/show?id=696730966a0' target=_blank style='color:#2F92EE;'>#冠脉搭桥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30966, encryptionId=696730966a0, topicName=冠脉搭桥)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=710114309336, createdName=yese, createdTime=Thu Sep 12 04:44:00 CST 2019, time=2019-09-12, status=1, ipAttribution=)]
    2019-09-12 yese

相关资讯

JACC:二尖瓣修复术后的远期预后研究

二尖瓣修复术已经成为退行性二尖瓣反流(MR)患者的标准治疗方法,但其远期预后尚不清楚。本研究的目的旨在评估二尖瓣修复术对MR的远期影响。本研究纳入分析了1234名(平均年龄59岁,男性占70.4%)接受二尖瓣修复术的MR患者,平均随访时间为13年(8-34年)。在第20年,不用再手术的患者生存率为60.4%(95%Cl:56.2%-64.2%),心脏和瓣膜相关的累积死亡率为12%,非心脏相关死亡率

JACC:生物假体主动脉瓣置换术后抗凝治疗对患者短期预后无明显影响

目前,关于抗凝治疗对假体主动脉瓣置换术(AVR)后瓣膜血流动力学和临床预后的影响尚缺乏,本研究的目的旨在评估抗凝治疗对生物假体AVR术后患者预后的影响。本研究纳入分析了4832名接受生物假体AVR手术治疗的患者(经导管主动脉瓣置换术[TAVR] n=3889;外科主动脉瓣置换术[SAVR] n=943),经基线因素调整分析后发现,出院接受抗凝治疗患者在主动脉瓣平均压差和主动脉瓣大小方面与未接受抗凝

JACC:FDG在不同动脉组织摄入情况的分析研究

动脉18-氟脱氧葡萄糖(FDG)PET检测被认为是测量动脉粥样硬化斑块巨噬细胞的方法,并被用来评估疾病的活动度。本研究的目的旨在评估分析不同动脉组织对FDG的摄入情况及其对PET信号的影响。本研究对野生型和D374Y-PCSK9转基因实验猪进行了高脂高胆固醇饮食喂食从而诱导动脉粥样硬化的形成,并对其进行FDG-PET检测。结果显示,实验猪的动脉FDG-PET图像信号和人类相似,建模方法表明FDG-

复杂性心律失常如何用药?循证证据推动通络中药走上国际舞台

9月7日,在武汉召开的第七届中西医结合血管病学大会上,南京医科大学第一附属医院曹克将教授公布了一个好消息,由他主持的“参松养心胶囊治疗窦性心动过缓伴室性早搏的循证医学研究”相关论文于不久前在国际权威期刊《补充与替代医学》(影响因子2.064)上发表。

第七届中西医结合血管病学大会:保护微小血管就是保护心脑健康

9月7日,在武汉召开的第七届中西医结合血管病学大会上,中国工程院院士张运教授、中国工程院院士吴以岭教授、中国医学科学院阜外医院杨跃进教授等中西医专家齐聚一堂,就血管病防治展开深入的学术交流。

JACC:阿利罗库单抗可明显改善急性冠脉综合征患者预后

急性冠脉综合征(ACS)患者和有既往冠脉搭桥手术史(CABG)患者是心血管疾病的高危人群,本研究的目的旨在评估联合阿利罗库单抗和他汀类药物对有CABG手术史的ACS患者的疗效。本研究将18924名接受高强度他汀类药物治疗但致动脉粥样硬化脂蛋白水平仍较高的ACS患者,随机分成皮下注射阿利罗库单抗组和安慰剂组。平均随访时间是2.8年,主要终点事件是主要心血管不良事件(MACE),包括冠心病、非致死性心